Absci CorpABSIEarnings & Financial Report
Absci Corp is a synthetic biology and AI-powered biotech firm focused on advancing next-generation biologic drug discovery and development. It delivers integrated protein engineering solutions to pharmaceutical and biopharmaceutical partners, enabling faster creation of novel antibodies, therapeutic proteins and other complex biologic candidates to address unmet global medical needs.
ABSI Q4 FY2025 Key Financial Metrics
Revenue
$650.0K
Gross Profit
N/A
Operating Profit
$-31.0M
Net Profit
$-29.6M
Gross Margin
N/A
Operating Margin
-4775.5%
Net Margin
-4548.0%
YoY Growth
-2.3%
EPS
$-0.19
Absci Corp Q4 FY2025 Financial Summary
Absci Corp reported revenue of $650.0K (down 2.3% YoY) for Q4 FY2025, with a net profit of $-29.6M (down 2.0% YoY) (-4548.0% margin).
Key Financial Metrics
| Total Revenue | $650.0K |
|---|---|
| Net Profit | $-29.6M |
| Gross Margin | N/A |
| Operating Margin | -4775.5% |
| Report Period | Q4 FY2025 |
Absci Corp Annual Revenue by Year
Absci Corp annual revenue history includes year-by-year totals (for example, 2024 revenue was $4.5M).
Absci Corp Quarterly Revenue & Net Profit History
Absci Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $650.0K | -2.3% | $-29.6M | -4548.0% |
| Q2 FY2025 | $593.0K | -53.3% | $-30.6M | -5155.0% |
| Q1 FY2025 | $1.2M | +31.3% | $-26.3M | -2234.6% |
| Q4 FY2024 | $665.0K | +96.7% | $-29.0M | -4358.3% |
| Q3 FY2024 | $1.7M | +128.6% | $-27.4M | -1610.7% |
| Q2 FY2024 | $1.3M | -62.3% | $-24.8M | -1948.8% |
| Q1 FY2024 | $898.0K | -29.2% | $-22.0M | -2447.1% |
| Q3 FY2023 | $744.0K | -68.6% | $-22.0M | -2956.2% |
Income Statement
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $744000 | $898000 | $1.3M | $1.7M | $665000 | $1.2M | $593000 | $650000 |
| YoY Growth | -68.6% | -29.2% | -62.3% | 128.6% | 96.7% | 31.3% | -53.3% | -2.3% |
Balance Sheet
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $236.3M | $274.9M | $255.5M | $235.2M | $213.6M | $232.4M | $209.9M | $216.3M |
| Liabilities | $39.9M | $34.8M | $34.0M | $33.9M | $34.5M | $33.7M | $36.5M | $26.8M |
| Equity | $196.4M | $240.1M | $221.5M | $201.3M | $179.1M | $198.8M | $173.4M | $189.4M |
Cash Flow
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-10.4M | $-17.9M | $-16.8M | $-20.7M | $-17.0M | $-21.8M | $-16.9M | $-29.2M |